Trials / Completed
CompletedNCT01220076
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Institut Cancerologie de l'Ouest · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +. The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of TAM will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tamoxifen |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2016-10-01
- Completion
- 2016-10-01
- First posted
- 2010-10-13
- Last updated
- 2021-03-12
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01220076. Inclusion in this directory is not an endorsement.